No Data
No Data
hutchmed (china) will hold an expert meeting to discuss immune thrombocytopenia
Grantsberry reported on August 21 that Hutchmed (China) announced today that it will hold a medical expert conference, inviting a professor and opinion leader in the field of immune thrombocytopenia to discuss the prospects for the treatment of immune thrombocytopenia. The meeting will be held on the evening of Wednesday, August 28, 2024, at 7:00 pm Hong Kong time via online streaming. This event will be conducted in Mandarin Chinese and can be accessed by registering. Investors interested in listening to the live webcast should visit the website before the meeting starts to download the required software. The meeting minutes (including English
Hutchmed Scores U.S. Success With Cancer Drug, but Profits Still Dip
Shares of US-listed Chinese Stocks Are Trading Lower Ahead of Upcoming Economic Data.
Hong Kong stock market movements: Hutchmed (China) Pharmaceuticals Ltd. (00013) rose more than 4% in intraday trading. The overseas sales of Fruquintinib exceeded expectations. Selpercatinib is expected to be approved in the second half of the year.
Hutchmed (China) (0013) rose over 4% during the day, as of press time, up 2.57%, to HK$31.95 with a turnover of HK$43.8172 million.
Grant options under the stock option plan and rewards under the long-term incentive plan of hutchmed (china).
Hutchmed (China) (00013) announced that on August 5, 2024, it had granted stock options under the stock option plan adopted by Hutchmed (China) in 2015 and awards under the long-term incentive plan adopted by Hutchmed (China) in 2015. Hutchmed (China) granted its stock options under the stock option plan to Dr. Weiguo Su (Executive Director, CEO and Chief Scientific Officer), a person responsible for complying with the UK market abuse regulations, subject to performance targets. A total of 1.4058 million ordinary shares with a nominal value of USD 0.10 each in the company's share capital are available for subscription, subject to the acceptance of the grantee.
Hutchmed (China) (00013.HK): Granted stock options under the share option scheme and rewards under the long-term incentive plan.
Hutchmed (China) (00013.HK) announced on August 6th that it has granted options under the share option scheme ("Option Scheme") adopted by Hutchmed (China) in 2015 and awards under the long-term incentive plan ("LTIP") adopted by Hutchmed (China) in 2015 on August 5th, 2024. Hutchmed (China) granted options under its share option scheme to Wei-guo Su (Executive Director, CEO and Chief Scientific Officer), subject to performance targets; provided that the offeree accepts, to subscribe for a total of 1,405,767 shares of the company's stock with a face value of 0.10 per share.